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The introduction of highly active anti-retroviral therapy (HAART) has markedly decreased the rates of 
opportunistic infections, the progression to AIDS, 
and the overall mortality for HIV-infected patients.1 
In some patients, however, the effective immune 
reconstitution that follows HAART can result in 
an exuberant inflammatory response leading to 
paradoxical clinical deterioration. The presence of 
IRIS does not mean that HAART has failed. In fact 
it shows that the treatment is effective.
In this report, we describe five patients at Sultan 
Qaboos University Hospital, Oman, who developed 
IRIS shortly after the initiation of HAART. In 
addition, a literature review on the epidemiology, 
aetiology, risk factors, pathogenesis, diagnosis 
and management of infection-related IRIS is also 
included in this report.
Case One 
A 23 year-old male was diagnosed in 2002 
with HIV-1 infection when he presented with 
Cryptococcus neoformans meningitis. At diagnosis, 
his CD4 count was 58cells/mm3 and the HIV-1 viral 
load 110,000 ribonucleic acid (RNA) copies/ml. 
He received amphotericin B 1mg/kg intravenously 
(IV) daily for the first 2 weeks, then flucanozole 400 
mg PO (per os, i.e. orally) daily for 8 weeks followed 
by maintenance therapy. Cotrimoxazole was started 
for pneumocystis pneumonia (PCP) prophylaxis. 
HAART (zidovudine, lamivudine, indinavir) was 
started in March 2003, but was later stopped due 
to poor compliance. In January 2007, he was again 
restarted on HAART (zidovudine, lamivudine, 
lopinavir/ritonavir). His pre-HAART CD4 count 
was 35cells/mm3 and HIV-1 viral load was 159,000 
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aBStract: Immune reconstitution inflammatory syndromes (IRIS) in patients with acquired immune deficiency 
syndrome (AIDS) are characterised by atypical manifestations of opportunistic pathogens. These occur in patients 
experiencing improvement in CD4 cell counts following receipt of highly active anti-retroviral therapy (HAART). 
Although well established as a syndrome, IRIS still presents challenges in diagnosis and management. We report 
five cases of IRIS with diverse clinical presentations and due to different infectious aetiologies. A review of the 
published literature on this syndrome is also included.
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RNA copies/ml. Seven weeks later, he presented 
with fever and progressive pain and swelling of the 
right elbow and knee joints. Clinical examination 
revealed swollen, warm and tender right elbow 
and right knee with effusion and severe restriction 
of movements. A whole body bone scintigraphy, 
using technetium-99m-methylene diphosphonate 
(Tc99m-MDP), was done as well as a magnetic 
resonance imaging (MRI) scan of the right elbow 
and knee joints [Figures 1 and 2, respectively].
Multifocal septic arthritis of the right elbow 
and knee joints with osteomyelitis was diagnosed. 
The right elbow and knee joints were aspirated and 
drained thick greenish pus. A Ziehl-Neelsen stain 
of the aspirate from both sites showed sheets of 
acid fast bacilli. The patient underwent drainage 
and debridement of the affected bones; tissues were 
also sent for mycobacterium and fungal culture. 
Standard quadruple antituberculous therapy (ATT) 
and clarithromycin were started while awaiting the 
culture results. HAART was continued and non-
steroidal anti-inflammatory drugs (NSAIDs) were 
prescribed.
A repeat CD4 count at this presentation 
showed it had risen to 185 cells/mm3 and HIV-
1 viral load had dropped to 3350 RNA copies/
ml. The culture of the aspirate of both joints and 
the humeral and femoral bone biopsy revealed 
growth of non Mycobacterium avium complex 
(non-MAC), non-tuberculous Mycobacterium 
which could not be further identified in the public 
health laboratory. The isolate was sensitive only to 
Figure 1: Three -phase bone scintigraphy delayed 
images show increased radiotracer uptake in right 
elbow and knee.
Figure 2a: MRI Right elbow (STIR sequence in coronal 
plane) demonstrates bone marrow oedema in the lateral 
epicondyle associated with joint effusion and soft tissue 
swelling. 
Figure 2b: Magnetic resonance image of right knee 
T1W FS CE in the sagittal plane showing intra osseous 
abscesses in condyles (not in picture) and patella with 
joint effusion, synovitis and bone marrow oedema.
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ciprofloxacin and clarithromycin while resistant to 
all standard antitubercular (ATT) drugs including 
rifampicin, ethambutol and aminoglycosides. The 
ATT treatment was stopped while ciprofloxacin 
and clarithromycin were continued in addition to 
HAART. The patient made a full recovery and has 
remained asymptomatic to date.
Case Two 
A 38 year-old woman was diagnosed in December 
2006 with HIV-I infection after presenting with 
Pneumocystis jiroveci pneumonia (PCP) [Figure 3]. 
She had a CD4 count of 8 cells/mm3 and the HIV-1 
viral load of 314,000 RNA copies/ml at diagnosis. 
Three weeks later she was started on HAART 
(zidovudine, lamivudine and efavirenz). About four 
weeks after commencing HAART, she developed 
fever, headache and vomiting. The clinical 
examination showed neck stiffness and positive 
Kernig’s sign. The computed tomography (CT) 
scan of the brain was normal. A lumbar puncture 
was performed and the subsequent India ink stain 
and Cryptococcus antigen were both positive 
in the cerebrospinal fluid (CSF). Cryptococcus 
neoformans was later isolated from the CSF. The 
patient received liposomal amphotericin 5mg/kg IV 
daily for 2 weeks followed by fluconazole 400 mg 
PO daily for 8 weeks and later maintained on oral 
fluconazole 200 mg daily. HAART was discontinued 
temporarily during the initial phase of treatment 
(the first two weeks), but was later restarted. At this 
presentation, the CD4 count was 35cells/mm3 and 
the HIV-1 viral load was 35,000 RNA copies/ml. 
The patient had a full recovery with follow-up CSF 
cultures documenting sterility.
Case Three 
A 57 year-old man was diagnosed in August 2006 
with HIV-1 infection when he presented with 
biopsy proven Toxoplasma gondii brain abscesses. 
The CD4 count at presentation was 85cells/mm3 
and the HIV-1 viral load was >750,000 RNA 
copies/ml. He was treated with a combination of 
pyrimethamine 75 mg PO daily, sulfadiazine 1g PO 
6 hourly and folinic acid 15 mg PO daily for 6 weeks. 
He was afterwards put on maintenance therapy. 
The patient’s symptoms improved as a result of 
this treatment. A follow up MRI brain confirmed 
resolution of the lesions. HAART (zidovudine, 
lamivudine, abacavir) was then started. Eight weeks 
later, he presented with fever, abdominal pain 
and diarrhoea. The clinical examination revealed 
jaundice and tenderness at the right upper quadrant 
of the abdomen. Acute cholangitis was suspected. 
An MRI scan of the abdomen was done [Figure 4] 
and revealed dilated intrahepatic biliary ducts with 
the contrast uptake suggesting inflammation.
The patient underwent upper gastrointestinal 
(GI) endoscopy, which showed an ulcerative 
necrotic lesion and areas of hyperaemia involving 
Figure 3: Frontal radiograph chest showing bilateral 
reticular opacities mainly in mid and lower lungs. 
Figure 4: Magnetic resonance imaging scan of the 
abdomen - T2W FS in the axial plane - reveals dilated 
intra hepatic bile ducts with signs of cholangitis.
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the entire duodenum. A duodenal aspirate and 
biopsy showed the presence of Cryptosporidium. 
The stool was also positive for Cryptosporidium. 
The test for cytomegalovirus by polymerase chain 
reaction (CMV-PCR) was negative. The CD4 count 
at this presentation was 287cells/mm3 and the HIV-
1 viral load was 4670 RNA copies/ml. The patient 
was started on paromomycin 500 mg PO three 
times daily and azithromycin 500 mg PO once 
daily. The HAART was continued and a complete 
resolution of the symptoms was achieved. A follow-
up upper GI endoscopy and MRI six weeks later 
were both normal.
Case Four
A 30 year-old woman was diagnosed in 2003 
with HIV-1 infection during pregnancy. The CD4 
count was 20 cells/mm3 and the HIV-1 viral load 
was >750,000 RNA copies/ml. She was then 
lost to follow-up. In 2005, she presented with 
severe CMV and Candida esophagitis (diagnosis 
made by upper GI endoscopy and oesophageal 
biopsy). She was treated with flucanozole 400 mg 
intravenously (IV) daily and ganciclovir 5mg/kg IV 
twice daily. Pentamidine 300 mg via aerosol once 
monthly was also started for prophylaxis against 
PCP as the patient had a severe allergy to sulpha. 
HAART (zidovudine, lamivudine, indinavir) was 
started. Three weeks later, the patient presented 
with generalised tonic-clonic seizures. The clinical 
examination was normal. An urgent MRI brain 
scan [Figure 5a & b ] was consistent with cerebral 
toxoplasmosis.
The serology for toxoplasmosis was positive 
in both immunoglobin G and M (IgG & IgM). A 
working diagnosis of cerebral toxoplasmosis was 
made and the patient was started on combination 
of pyrimethamine 75 mg PO daily, clindamycin 450 
mg PO three times daily and folinic acid 15 mg PO 
daily for 6 weeks and later was put on maintenance 
therapy.
The HAART was discontinued temporarily. The 
CD4 count at this presentation had risen to 84 cells/
mm3 and HIV-1 viral load had fallen to 7130 RNA 
copies/ml. The patient remained asymptomatic 
during this period with no recurrence of convulsions. 
A follow-up MRI brain scan at the end of 6 weeks 
of treatment confirmed complete resolution. The 
same HAART regimen was then resumed with no 
unwanted consequences.
Case Five
A 23 year-old man was diagnosed in October 2005 
with HIV-1 infection when he presented with 
uncomplicated Salmonella bacteraemia. The CD4 
count was 10 cells/mm3 and the HIV-1 viral load 
was >750,000 RNA copies/ml. The US Centers 
for Disease Control and Prevention (CDC) stage 
at diagnosis was B3. He received ciprofloxacin 
400 mg IV twice daily for two weeks. HAART 
Figure 5A & 5B: MRI Brain FLAIR and T1W CE sequences showing enhancing lesion with perilesional oedema in right 
parietal lobe.
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Discussion
We described five patients with advanced HIV-
1 infection in whom initiation of HAART have 
resulted in unmasking of an underlying occult 
opportunistic infection. The five cases have 
all the classical features suggestive of immune 
reconstitution inflammatory syndrome (IRIS). All 
five had advanced HIV disease with a very high 
viral load and low CD4 count at the initiation of the 
therapy (HAART). The paradoxical worsening and 
the presentation, with an opportunistic infection 
2–8 weeks after the initiation of HAART in all five 
cases, correlated with the drop in viral load and the 
rise in CD4 count. The variety of pathology in these 
five cases associated with IRIS is also remarkable 
and is consistent with the common rule of IRIS that 
‘anything is possible’.
The HAART for HIV infection has been one of 
the most dramatic progressions in the history of 
medicine. Since its introduction, HAART has led to 
significant declines in AIDS-associated morbidity 
and mortality.2 These benefits are, in part, a result of 
partial recovery of the immune system, manifested 
by increases in CD4+ T-lymphocyte counts and 
decreases in plasma HIV-1 viral loads.3
Soon after the introduction of HAART, 
(abacavir, lamivudine, efavarinz) was commenced. 
Cotrimoxazole was started for primary prophylaxis 
for PCP. Four weeks after the initiation of HAART, 
he developed fever with left-sided, enlarged, painful 
cervical lymph-nodes. Clinical examination showed 
multiple left-sided tender cervical lymph-nodes, the 
largest measuring 3 × 4 cm. Both liver and spleen 
were enlarged. 
The tuberculin skin test (TST) was non-reactive. 
The cervical lymph-node biopsy showed sheets of 
acid-fast bacilli. Standard quadruple ATT was 
commenced and the HAART suspended during the 
initiation phase of ATT; NSAIDs were added. The 
CD4 count at this presentation had risen to 32 cells/
mm3 and the HIV-1 viral load had fallen to 160,000 
RNA copies/ml. A culture of the lymph-node grew 
fully sensitive Mycobacterium tuberculosis. The 
ATT was continued and the same HAART regimen 
(but with the dose of efavarenz increased to 800 
mg daily) was reintroduced after completion of the 
initiation phase of ATT. There were no undue side 
effects. Full recovery was achieved with resolution 
of the lymphadenopathy and regression of the 
hepatosplenomegaly.








































































Note: *Patient died later from advanced metastatic Kaposi sarcoma
Legend: HAART = highly active anti-retroviral therapy; IRIS = immune reconstitution inflammatory syndrome; RNA = ribonucleic acid.
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clinicians noticed that some patients initiating 
HAART experienced unique symptoms during 
immune system recovery. In these patients, clinical 
deterioration occurs despite increased CD4+ T 
lymphocyte counts and decreased plasma HIV-1 
viral loads.4 This clinical deterioration is a result of 
an inflammatory response of the immune system 
to both intact subclinical pathogens and residual 
antigens. Because clinical deterioration occurs 
during immune recovery, this phenomenon has 
been described as immune restoration disease 
(IRD), immune reconstitution syndrome (IRS), and 
paradoxical reactions. Given the role of the host 
inflammatory response in this syndrome, the term 
immune reconstitution inflammatory syndrome 
(IRIS) has been proposed.5
IRIS can be defined as a pathological 
inflammatory response and paradoxical clinical 
deterioration as a result of HAART related immune 
recovery or reconstitution in HIV infected persons. 
In other words, IRIS is a syndrome that occurs 
because a patient develops an exuberant response to 
appropriate therapy. IRIS is now a widely recognised 
phenomenon that can complicate HAART.6, 7, 8
How IRIS develops is not yet well understood 
and its pathogenesis remains largely speculative. 
Current theories concerning the pathogenesis of 
the syndrome involve a combination of underlying 
antigenic burden, the degree of immune restoration 
following HAART, and host genetic susceptibility. 
These pathogenic mechanisms may interact and 
likely depend on the underlying burden of infectious 
or non-infectious agents. 
As illustrated in all the five cases above, the 
majority of patients who develop IRIS do so 
within the first 4 to 8 weeks after starting HAART. 
However, the interval between the start of HAART 
and the onset of IRIS is highly variable, ranging from 
less than 1 week to several months after HAART 
initiation.9 Furthermore, most patients who develop 
IRIS have had high viral loads and very low CD4+ 
T-lymphocyte (CD4+) counts. In this report, all five 
patients had CD4 counts of <100 cells/mm3 at the 
start of HAART. In addition, three patients had an 
HIV-1 viral load of >750,000 RNA copies/ml.
The frequency of IRIS has not been reported 
conclusively and the overall incidence of the 
syndrome itself remains largely unknown, being 
dependent on the population studied and its 
underlying opportunistic infections burden. In the 
largest study of IRIS to-date, 31.6% of HIV infected 
patients developed IRIS while on HAART.10 In a 
large retrospective analysis examining all forms 
of IRIS, 25% of patients exhibited one or more 
disease episodes after initiation of HAART.4 Other 
cohort analyses examining all manifestations of 
IRIS estimate that 17–23% of patients initiating 
HAART will develop the syndrome.11,12 Another 
study demonstrated that up to one third of patients 
with HIV/tuberculosis co-infection who begin 
HAART in resource-limited countries could be 
at risk of developing tuberculosis-associated IRIS 
(also known as TB-IRIS).13
Collation of the clinical, immunological and 
immune-genetic data presented over the last 15 
years has identified risk factors for IRIS.4 A higher 
viral load and low CD4 T cell count at the start of 
HAART along with a rapid drop in viral load with 
treatment, as shown in all five cases in this report, 
has been found to be a favourable setting for IRIS 
to occur. In the affected patients, CD4 T cell counts 
are often <50 cells/mm3 at the start of HAART and 
subsequently increase more than 2–4 fold during 
the 12 months after initiation of HAART, and a 
significant decrease in HIV load of more than 2 
log10 copies/ml is often noted.14 
IRIS manifestations are diverse and depend on 
the infectious or non-infectious agent involved. 
These manifestations have not been precisely 
defined. In general, and as illustrated in the case 
reports above, they are characterised by fever and 
worsening of the clinical manifestations of the 
underlying opportunistic infection. These clinical 
manifestations may be at the site of a previously 
recognised opportunistic disease (none of our 
patients) or may “unmask” disease at new sites not 
previously known to be infected by the pathogen 
(none of our patients). They may also represent a 
response to a previously unrecognised additional 
pathogen (all five patients reported here). A 
paradoxical clinical worsening of a known condition 
or the appearance of a new condition after initiating 
therapy characterises the syndrome.
Mycobacterium tuberculosis (TB) is among the 
most frequently reported pathogens associated 
with IRIS. The commonest clinical manifestations 
of TB-IRIS are fever, lymphadenopathy and 
worsening respiratory symptoms.13 In most studies, 
TB-IRIS occurs within two months of HAART 
initiation. These studies suggest that the onset of 
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Mycobacterium-associated IRIS is relatively soon 
after initiation of HAART, and clinicians should 
maintain a high level of vigilance during this period.
The last patient in our report (Case Five) 
was a classic case of TB-IRIS. He presented with 
fever and cervical lymph-nodes enlargement 
shortly (four weeks) after initiation of HAART. 
Hepatosplenomegaly probably signifies wide-
spread TB disease and its subsequent regression on 
ATT further supports this hypothesis. 
In addition to Mycobacterium tuberculosis, 
nontuberculous mycobacteria are also frequently 
reported as causative pathogens in IRIS. 
Mycobacterium avium complex (MAC) remains the 
most frequently reported atypical mycobacterium 
linked with IRIS. Other atypical mycobacteria are 
rarely associated with IRIS.
The first patient in our series (Case One) had a 
nontuberculous Mycobacterium that was not MAC 
(and could not be further identified) which resulted 
in a severe form of multiple-site osteomyelitis. 
This disease manifested shortly after introduction 
of HAART (seven weeks later). Furthermore, it 
occurred at the time of marked immune recovery 
and marked improvement in CD4 count (CD4 
count had risen 4 to 5 fold by then).
Soon after the introduction of HAART, it was 
observed that some patients presented with an initial 
or recurrent episode of cryptococcal meningitis 
during the first few weeks of therapy;15 however, 
IRIS with cryptococcal meningitis is rare.16,17 The 
most common IRIS syndrome associated with 
cryptococcal infection is lymphadenitis.
IRIS was reported in 30–33% of HIV-infected 
patients with Cryptococcus neoformans after the 
initiation of HAART.18 Lower CD4-cell count and 
higher HIV-RNA concentrations at the onset of 
infection correlated with a higher risk of IRIS.18 
Patients with IRIS also had a greater reduction in 
HIV-RNA concentration within 90 days of HAART 
initiation,19 and had a greater fungal burden at 
the onset of infection.18 Furthermore, initiation 
of HAART within 30–60 days of the treatment of 
fungal infection has been associated with a higher 
risk of IRIS.20
The second patient (Case Two) in our 
report presented with an initial, first episode of 
cryptococcal meningitis while on HAART (3 weeks 
later). She had an extremely low CD4 count at the 
time of the initiation of HAART (CD4 8 cells/mm3) 
and had a dramatic immune recovery with a 4-fold 
CD4 count rise and >1 log reduction in the HIV-1 
viral load at time of presentation.
The number of reports of IRIS associated with 
parasitic diseases is small but increasing. Only two 
cases of suspected IRIS associated with toxoplasma 
encephalitis have been reported in published 
literature. In one case, no clinical details were 
given.12 In the other, an HIV-infected patient with 
a nadir CD4 cell count of 83 cells/mm3 presented 
with a focal seizure after 3 weeks of HAART.21 
The fourth patient in this report (Case Four) 
presents, to our knowledge, only the third reported 
case in the literature of IRIS associated with 
toxoplasma encephalitis. This patient presented 
with generalised seizures three weeks after initiation 
of HAART. He had an exceptionally low CD4 count 
(CD4 count 2 years earlier was 20cells/mm3) and a 
very high HIV-1 viral load (>750,000 RNA copies/
ml) at the time of initiation of HAART. He had a 
dramatic immune recovery with a 4-fold CD4 count 
rise and major reduction in the HIV-1 viral load of 
> 2 log reduction at the time of presentation with 
cerebral toxoplasmosis. The diagnosis of cerebral 
toxoplasmosis was made on the basis of positive 
serology, multiple ring-enhancing intra-cerebral 
lesions on an MRI scan and a positive response 
to treatment for toxoplasmosis with complete 
resolution on follow-up brain imaging. 
Of interest is that there are no frequent reports 
in the published literature of IRIS associated with 
Cryptosporidium infection. We here report a rare 
case of Cryptosporidium infection associated with 
IRIS.
Our patient (Case Three) presented eight 
weeks following initiation of HAART with fever, 
abdominal pain and diarrhoea. This occurred at a 
time where immune recovery was dramatic (CD4 
count rise from 85 to 287 cells/mm3) and HIV-1 
viral load reduction was substantial (HIV-1 viral 
load reduction > 2 log). Endoscopy proven extensive 
duodenal inflammation and ulcerations were found 
in addition to clinical, biochemical, and an MRI 
assisted diagnosis of cholangitis. Furthermore, the 
duodenal aspirate and multiple duodenal biopsies 
confirmed the presence of Cryptosporidium. The 
stool sample was also positive for Cryptosporidium. 
No other aetiologies were identified. The resolution 
of symptoms and normal subsequent endoscopy 
further supports the diagnosis of IRIS associated 
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Cryptosporidium. To our knowledge this is the first 
reported case in the literature.
Diagnosis of IRIS is clinically challenging and 
involves differentiation between the progression of 
the initial opportunistic infection (OI) (including 
the possibility of antimicrobial resistance and 
treatment failure); development of a new OI; 
unrelated organ dysfunction, or drug toxicity. IRIS 
should be suspected in patients who show clinical 
or radiologic deterioration following initiation of 
HAART accompanied with improvement in CD4 
count and viral load.
Since there is no diagnostic test for IRIS, 
confirmation of the disease relies heavily upon case 
definitions incorporating clinical and laboratory 
data. French et al.7 and Shelburne et al.22 published 
two of the most widely used IRIS case definitions 
in the literature. In a recent article, published in 
the Clinical Infectious Diseases journal, Haddow 
et al. proposed a revised case definition of IRIS 
incorporating both definitions along with separate 
definitions for unmasking and paradoxical IRIS.23
The current management of IRIS remains 
controversial and therapy for IRIS is largely empiric. 
There are no well-controlled trials concerning the 
management of IRIS. All evidence in the literature 
regarding the management of IRIS is found in 
case reports and small case series reporting on 
management practice. Furthermore, no clear 
guidelines exist regarding the continuation of 
HAART during IRIS; therefore, the decision to 
continue HAART in spite of IRIS should be based 
on the clinical scenario. If the pathogens involved 
in IRIS are not amenable to specific treatment, 
or if life-threatening events occur and steroids 
are ineffective, one should consider suspending 
antiretroviral therapy.24
Symptomatic therapy for IRIS can be tried 
with NSAIDs and steroids. Immune modulation in 
some instances is warranted, but specific drugs and 
protocols are lacking. Other modalities tried include 
thalidomide and intravenous immunoglobulin 
(IVIG)
In our report, HAART was discontinued 
temporarily in three patients (cases Two, Four and 
Five). These patients had cryptococcal meningitis, 
cerebral toxoplasmosis and TB lymphadenitis 
respectively. HAART was discontinued in the 
patient with cryptococcal meningitis during the 
induction phase of treatment (first two weeks) and 
was restarted thereafter with no complications. In 
the patient with cerebral toxoplasmosis, HAART 
was suspended until complete resolution of the 
brain abscesses and associated oedema (six weeks). 
HAART was then reintroduced with no problems. 
In both scenarios, HAART was suspended 
temporarily to minimise the inflammatory process 
and its potential unwanted consequences in a 
critical site (brain). In the patient with TB-IRIS, 
HAART was suspended during the initiation phase 
of ATT (first two months) only to enhance patient 
compliance with TB treatment. Both HAART and 
ATT were later combined resulting in cure.
HAART was continued without interruption in 
the remaining two patients (cases One and Three). In 
the patient with atypical Mycobacterium associated-
osteomyelitis (Case One), in addition to continuing 
HAART, NSAIDs were used. Specific therapy with 
clarithromycin and moxifloxacin resulted in cure. 
In the patient with Cryptosporidium induced 
duodenitis and cholangitis (Case Three), HAART 
was continued and specific prolonged treatment 
with paromomycin and azithromycin was given 
resulting in clearance of the parasitic infection and 
subsequent cure. 
Although some IRIS cases are short-lived, or 
cause minor clinical problems, others may result 
in significant morbidity and sometimes death. 
However, IRIS does not appear to have favourable 
or unfavourable implications about patient survival, 
with the possible exception of IRIS associated with 
cryptococcal meningitis.10
To date, with exception of the patient with TB-
IRIS (Case Five), who died from disseminated Kaposi 
sarcoma, the other four patients have remained 
well and had optimal clinical, immunologic and 
virological responses on HAART.
Conclusion
Our cases establish the fact that IRIS is a significant 
problem in the post HAART era and is associated 
with several challenges for the treating physicians. 
As the use of HAART increases around the world 
(including developing countries where a large 
number of severely immune-deficient patients are 
being given HAART), physicians managing patients 
with HIV infection will encounter increasing 
numbers of patients with IRIS. The inclusion of 
IRIS in the differential diagnosis of a patient who 
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presents with an inflammatory process after 
initiating HAART allows for a focused approach to 
diagnosis and therapy. Further studies are needed 
to help us to understand how to deal with this 
clinically significant problem. Guidelines for the 
management of IRIS and the use of HAART during 
IRIS also need to be developed.
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